Immunologic Research

, Volume 31, Issue 1, pp 37–46 | Cite as

The role of C5b-9 terminal complement complex in activation of the cell cycle and transcription

  • Matthew Fosbrink
  • Florin Niculescu
  • Horea Rus


Activation of the complement system plays an important role in innate and acquired immunity. Activation of complement and subsequent formation of C5b-9 channels on the surface of cellular membranes leads to cell lysis. When the number of channels assembled on the surface of nucleated cells is limited, C5b-9 doses not cause lysis, but instead can induce cell-cycle progression by activating signal transduction pathways, transcription factors, and key components of the cell-cycle machinery. Cell-cycle induction by C5b-9 is dependent on the activation of phosphatidylinositol 3-kinase and the ERK1 pathway in a Gi protein-dependent manner. Cell-cycle activation is regulated, in part, by activation of proto-oncogene c-jun and AP1 DNA binding activity. C5b-9 induces sequential activation of CDK4 and CDK2, leading to G1/S-phase transition and cellular proliferation. RGC-32 is a novel gene whose expression is induced by C5b-9. RGC-32 may play a key role in cell-cycle activation by increasing cyclin B1-CDC2 activity. C5b-9-mediated cell-cycle activation plays an important role in cellular proliferation and proctection from apoptosis.

Key Words

C5b-9 terminal complement complex Cell cycle Proto-oncogenes Signal transduction Transcriptional regulation RGC-32 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shin ML, Rus HG, Niculescu FI: Membranes attack by complement: assembly and biology of the terminal complement complexes. In: Lee A, ed. Biomembranes, vol. 4. JAI Press, 1996, pp. 123–149.Google Scholar
  2. 2.
    Frank MM: Complement system. In: Frank MM AK, Claman HN, Unanue ER, ed. Samter's Immunologic Diseases. Little, Brown and Company, Boston, 1995, pp. 331–362.Google Scholar
  3. 3.
    Wallis R: Structural and functional aspects of complement activation by mannose-binding protein. Immunobiology 2002;205:433–445.PubMedCrossRefGoogle Scholar
  4. 4.
    Shin ML, Carney DF Cytotoxic action and other metabolic consequences of terminal complement proteins. Prog Allergy 1988;40:44–81.PubMedGoogle Scholar
  5. 5.
    Morgan BP, Campbell AK: The recovery of human polymorphonuclear, leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem. J 1985;231:205–208.PubMedGoogle Scholar
  6. 6.
    Gee AP, Boyle MD, Borsos T: Distinction between C8-mediated and C8/C9-mediated hemogysis on the basis of independent 86Rb and hemoglobin release. J Immunol 1980;1241905–1910.PubMedGoogle Scholar
  7. 7.
    Dalmasso AP, Benson BA: Lesions, of different functional size produced by human and guinea pig complement in sheep red cell membranes. J Immunol 1981;127: 2214–2218.PubMedGoogle Scholar
  8. 8.
    Ramm LE, Whitlow MB, Mayer MM: The relationship between channel size and the number of C9 molecules in the C5b-9 complex. J Immunol 1985;134: 2594–2599.PubMedGoogle Scholar
  9. 9.
    Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML: Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci USA 1983;80:3816–3820.PubMedCrossRefGoogle Scholar
  10. 10.
    Papadimitriou JC, Ramm LE, Drachenberg CB, Trump BF, Shin ML: Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991;147:212–217.PubMedGoogle Scholar
  11. 11.
    Morgan BP, Dankert JR, Esser AF: Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987;138246–253.PubMedGoogle Scholar
  12. 12.
    Carney DF, Hammer CH, Shin ML: Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol 1986;137: 263–270.PubMedGoogle Scholar
  13. 13.
    Carney DF, Lang TJ, Shin ML: Multiple gignal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990;145:623–629.PubMedGoogle Scholar
  14. 14.
    Niculescu F, Rus H, Shin ML: Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem 1994;269:4417–4423.PubMedGoogle Scholar
  15. 15.
    Kraus S, Fishelson Z: Cell desensitization by C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Euro J Immunol 2000: 30:1272–1280.CrossRefGoogle Scholar
  16. 16.
    Kraus S, Seger R, Fishelson Z: Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 2001; 201:366–374.CrossRefGoogle Scholar
  17. 17.
    Sherr CJ: Cancer cell cycles. Science 1996;274: 1672–1677.PubMedCrossRefGoogle Scholar
  18. 18.
    Smit VA, Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 2001;1519:1–12.Google Scholar
  19. 19.
    van den Heuvel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050–2054.PubMedCrossRefGoogle Scholar
  20. 20.
    Rus HG, Niculescu FI, Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001;180:49–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Niculescu F, Badea T, Rus H: Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 1999;142:47–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Dashiell SM, Rus H, Koski CL: Ternimal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 2000; 30:187–198.PubMedCrossRefGoogle Scholar
  23. 23.
    Niculescu F, Hila S Fosbrink M, et al.: Endothelial cell proliferation induced by sublytic C5b-9 requires the activation of p70S6 kinase through a mechanism involving the G-protein dependent activation of phosphatidylinositol 3-kinase. Int Immunopharmacol 2002;318:1219A.Google Scholar
  24. 24.
    Rus HG, Niculescu F, Shin ML: Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol 1996;156:4892–900.PubMedGoogle Scholar
  25. 25.
    Rus H, Niculescu F, Badea T, Shin ML: Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. Immunopharmacology 1997;38:177–187.PubMedCrossRefGoogle Scholar
  26. 26.
    Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD: cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 1990;250:805–808.PubMedCrossRefGoogle Scholar
  27. 27.
    Marraccino RL, Firpo EJ, Robert JM, Activation of the p34CDC2 protein kinase at the start of S phase in the human cell cycle. Mol Biol Cell 1992;3:389–401.PubMedGoogle Scholar
  28. 28.
    Moore JD, Kirk JA, Hunt T: Unmasking the S- phase-promoting potential of cyclin B1. Science 2003;300: 987–990.PubMedCrossRefGoogle Scholar
  29. 29.
    Ortega S, Prieto I, Odajima J, et al.: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Shankland SJ, Pippin JW, Couser WG: Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 1999; 56:538–548.PubMedCrossRefGoogle Scholar
  31. 31.
    Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 2003;111:877–885.PubMedCrossRefGoogle Scholar
  32. 32.
    Badea TC, Niculescu FI, Soane L, Shin ML, Rus H: Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oliogo-dendrocytes. J Biol Chem 1998;273:26977–26981.PubMedCrossRefGoogle Scholar
  33. 33.
    Badea T, Niculescu F, Soane L, et al.: RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 2002;277: 502–508.PubMedCrossRefGoogle Scholar
  34. 34.
    Halperin JA, Taratuska A, Nicholson-Weller A: Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993;91:1974–1978.PubMedCrossRefGoogle Scholar
  35. 35.
    Benzaquen LR, Nicholson-Weller A, Halperin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994;179: 985–992.PubMedCrossRefGoogle Scholar
  36. 36.
    Zwaka TP, Torzewski J, Hoeflich A, et al.: The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. Faseb J 2003;17:1346–1348.PubMedGoogle Scholar
  37. 37.
    Mason JC, Lidington EA, Ahmad SR, Haskard DO: bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 2002;282:C578–587.PubMedGoogle Scholar
  38. 38.
    Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35–58.PubMedCrossRefGoogle Scholar
  39. 39.
    Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911–1912.PubMedCrossRefGoogle Scholar
  40. 40.
    Tapon N, Moberg KH, Hariharan IK: The coupling of cell growth to the cell cycle. Curr Opin Cell Biol 2001;13:731–737.PubMedCrossRefGoogle Scholar
  41. 41.
    Peng H, Takano T, Papillon J, Bijian K, Khadir A, Cybulsky AV: Complement activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular epithelial cells. J Immunol 2002;169:2594–2601.PubMedGoogle Scholar
  42. 42.
    Niculescu F, Rus H, van Biesen T, Shin ML: Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol 1997;158:4405–4412.PubMedGoogle Scholar
  43. 43.
    Aoudjit L, Stanciu M, Li H, Lemay S, Takano T: p38 mitogen-activated protein kinase protects glomerular epithelial cells from complement-mediated cell injury. Am J Physiol Renal Physiol 2003;285:F765–774.PubMedGoogle Scholar
  44. 44.
    Niculescu F, Hila S, Fosbrink M, Soane L, Rus H: Sublytic C5b-9 induces translational activation in human aortic endothelial cells. Role of p70 S6 kinase. Mol Immunol 2001;2–3:113.Google Scholar
  45. 45.
    Darnell JE, Jr.: The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res 1996;51:391–403; discussion 403–404.PubMedGoogle Scholar
  46. 46.
    Darnell JE, Jr.: STATs and gene regulation. Science 1997;277:1630–1635.PubMedCrossRefGoogle Scholar
  47. 47.
    Niculescu F, Soane L, Badea T, Shin M, Rus H: Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology 1999;42: 187–193.PubMedCrossRefGoogle Scholar
  48. 48.
    Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996;8:205–215.PubMedCrossRefGoogle Scholar
  49. 49.
    Murphy LO, MacKeigan JP, Blenis J: A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol 2004;24:144–153.PubMedCrossRefGoogle Scholar
  50. 50.
    Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131–136.PubMedCrossRefGoogle Scholar
  51. 51.
    Lang TJ, Badea TC, Wade R, Shin ML: Sublytic terminal complement attack on myotubes decreases the expression of mRNAs encoding muscle-specific proteins. J Neurochem 1997;68:1581–1589.PubMedCrossRefGoogle Scholar
  52. 52.
    Badea TD, Park JH, Soane L, et al.: Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes. J Neuroimmunol 2003;142:58–66.PubMedCrossRefGoogle Scholar
  53. 53.
    Kilgore KS, Schmid E, Shanley TP, et al.: Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattaractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997;150:2019–2031.PubMedGoogle Scholar
  54. 54.
    Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J: The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. Faseb J 2000;14:2370–2372.PubMedGoogle Scholar
  55. 55.
    Dashiell SM, Koski CL: Sublytic terminal complement complexes decrease PO Gene expression in Schwann cells. J Neurochem 1999;73:2321–2330.PubMedCrossRefGoogle Scholar

Copyright information

© Human Press Inc 2005

Authors and Affiliations

  • Matthew Fosbrink
    • 1
    • 2
  • Florin Niculescu
    • 2
  • Horea Rus
    • 2
    • 3
  1. 1.Toxicology ProgramUniversity of MarylandBaltimore
  2. 2.Department of PathologyUniversity of Maryland School of MedicineBaltimore
  3. 3.Department of NeurologyUniversity of Maryland School of Medicine and Veterans Administration Maryland Health Care System, Multiple Sclerosis Center of ExcellenceBaltimore

Personalised recommendations